Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open-label, Randomized Controlled Study Comparing Rituximab, Methotrexate, Cytarabine, and Penpulimab (R-MA-PD-1) Versus Rituximab, Methotrexate, and Cytarabine (R-MA) in Treatment-naive Patients With Primary Central Nervous System Lymphoma

NCT07764601 is registered in ClinicalTrials.gov with WEI XU as lead sponsor.

NCT NCT07764601
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07764601 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open-label, Randomized Controlled Study Comparing Rituximab, Methotrexate, Cytarabine, and Penpulimab (R-MA-PD-1) Versus Rituximab, Methotrexate, and Cytarabine (R-MA) in Treatment-naive Patients With Primary Central Nervous System Lymphoma
Lead sponsor
WEI XU
Phase
Not applicable
Overall status
Not yet recruiting
Start date
August 31, 2026
Completion date
August 31, 2029
Enrollment
58 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma, primary central nervous system lymphoma